Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVAXIM 80U Pediatric + TRIMOVAX
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
AVAXIM 80U Pediatric + TRIMOVAX is a combination vaccine regimen developed by Sanofi Pasteur for the prevention of hepatitis A, measles, mumps, and rubella in children. The regimen consists of AVAXIM 80U Pediatric, an inactivated vaccine containing the GBM strain of the hepatitis A virus (HAV) cultured on MRC-5 human diploid cells and adsorbed onto an aluminum adjuvant, and TRIMOVAX, a trivalent live-attenuated vaccine targeting the measles, mumps, and rubella viruses. Clinical evaluation in Phase 4 trials (such as HAF65) has demonstrated that the concomitant administration of these vaccines at separate injection sites in children aged 12-13 months is safe and does not interfere with the immunogenicity of the individual components, effectively inducing protective antibody titers against all four viral pathogens.
- Brand names
- AVAXIM 80U PediatricAVAXIM80U PediatricAVAXIM-80U PediatricTRIMOVAX
- Other names
- Inactivated hepatitis A vaccine + attenuated measles mumps rubella vaccineAVAXIM 80U-PediatricAVAXIM80U-PediatricAVAXIM-80U-PediatricTRIMOVAX
Beyond the preview
Go deeper on AVAXIM 80U Pediatric + TRIMOVAX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVAXIM 80U Pediatric + TRIMOVAX.